| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Diversoside does not have a well-defined molecular target. As a natural product, it may exhibit various biological activities, but specific targets have not been extensively characterized. The compound is primarily of interest as a natural product for phytochemical and pharmacological research. Further studies are needed to identify its molecular targets and mechanisms of action.
|
|---|---|
| ln Vitro |
Diversoside has not been extensively characterized for in vitro pharmacological activity. As a natural product from Notopterygium forbesii and Aster subspicatus, it may possess biological activities such as anti-inflammatory, antioxidant, or antimicrobial effects. However, quantitative in vitro data (e.g., IC50 values) are not readily available from publicly accessible sources. Further research is needed to establish its bioactivity profile.
|
| ln Vivo |
Diversoside has no reported in vivo pharmacological activity. It is not used as a therapeutic agent and has no approved clinical indications. As a natural product, it may have been used in traditional medicine contexts, but modern pharmacological studies are limited. No specific in vivo efficacy data are available.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for diversoside would typically involve screening against a panel of targets to identify potential biological activities. Given its saccharide structure, assays for glycosidase inhibition, lectin binding, or carbohydrate-binding protein interactions would be relevant. Anti-inflammatory activity could be assessed using COX or LOX inhibition assays. Antioxidant activity could be assessed using DPPH or ABTS radical scavenging assays. Specific published protocols are not available.
|
| Cell Assay |
In vitro cell-based assays for diversoside would involve culturing appropriate cell lines and treating them with the compound to assess effects on cell viability, inflammation, or oxidative stress. Cytotoxicity would be evaluated using MTT or LDH release assays. Anti-inflammatory activity could be assessed by measuring cytokine production in LPS-stimulated macrophages. Antioxidant activity could be assessed by measuring ROS levels using fluorescent probes. Specific protocols would need to be developed based on the research question.
|
| Animal Protocol |
In vivo animal studies for diversoside have not been reported in the literature. If conducted, such studies might involve oral or intraperitoneal administration in rodents to assess anti-inflammatory, antioxidant, or other pharmacological activities. Standard models for evaluating these activities include carrageenan-induced paw edema for anti-inflammatory effects and oxidative stress models for antioxidant effects. No specific data are available.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of diversoside have not been characterized. As a glycoside with a molecular weight of 494.53, it is expected to have limited oral bioavailability due to poor absorption and extensive first-pass metabolism. Glycosides are typically hydrolyzed by gut microbiota or intestinal enzymes to release the aglycone, which may then be absorbed. No specific PK data are available.
|
| Toxicity/Toxicokinetics |
The toxicity profile of diversoside has not been systematically evaluated. As a natural product, it may have a favorable safety profile, but this has not been confirmed in controlled toxicology studies. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
There have been reports that isophylloside has been found in Ferula diversivittata, and relevant data are available for reference.
Diversoside is a natural product isolated from Notopterygium forbesii and Aster subspicatus. It has the molecular formula C25H34O10 and a molecular weight of 494.53. The compound is classified as a saccharide natural product and is of research interest for phytochemical and pharmacological studies. Diversoside is not approved for clinical use and is available only for research purposes. |
| Molecular Formula |
C25H34O10
|
|---|---|
| Molecular Weight |
494.531
|
| Exact Mass |
494.215
|
| CAS # |
55062-36-7
|
| PubChem CID |
134714934
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.4
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
35
|
| Complexity |
765
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C/C(=C\COC1=CC2=C(C=C1)C=CC(=O)O2)/CC[C@H](C(C)(C)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O
|
| InChi Key |
FHSVEVZRJJWBAP-UFTFMSQISA-N
|
| InChi Code |
InChI=1S/C25H34O10/c1-14(10-11-32-16-7-5-15-6-9-20(27)33-17(15)12-16)4-8-19(25(2,3)31)35-24-23(30)22(29)21(28)18(13-26)34-24/h5-7,9-10,12,18-19,21-24,26,28-31H,4,8,11,13H2,1-3H3/b14-10+/t18-,19-,21-,22+,23-,24+/m1/s1
|
| Chemical Name |
7-[(E,6R)-7-hydroxy-3,7-dimethyl-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoct-2-enoxy]chromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0221 mL | 10.1106 mL | 20.2212 mL | |
| 5 mM | 0.4044 mL | 2.0221 mL | 4.0442 mL | |
| 10 mM | 0.2022 mL | 1.0111 mL | 2.0221 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
